| Trial of sodium phenylbutyrate–taurursodiol for amyotrophic lateral sclerosis S Paganoni, EA Macklin, S Hendrix, JD Berry, MA Elliott, S Maiser, ... New England Journal of Medicine 383 (10), 919-930, 2020 | 547 | 2020 |
| Long‐term survival of participants in the CENTAUR trial of sodium phenylbutyrate‐taurursodiol in amyotrophic lateral sclerosis S Paganoni, S Hendrix, SP Dickson, N Knowlton, EA Macklin, JD Berry, ... Muscle & nerve 63 (1), 31-39, 2021 | 197 | 2021 |
| Effects of PB‐TURSO on the transcriptional and metabolic landscape of sporadic ALS fibroblasts JA Fels, J Dash, K Leslie, G Manfredi, H Kawamata Annals of Clinical and Translational Neurology 9 (10), 1551-1564, 2022 | 21 | 2022 |
| Multidimensional analysis and therapeutic development using patient iPSC–derived disease models of Wolfram syndrome RA Kitamura, KG Maxwell, W Ye, K Kries, CM Brown, P Augsornworawat, ... JCI insight 7 (18), 2022 | 19 | 2022 |
| Effects of the investigational drug sodium phenylbutyrate-TUDCA (AMX0035) on the transcriptional and metabolic landscape of sporadic ALS fibroblasts JA Fels, J Dash, K Leslie, G Manfredi, H Kawamata bioRxiv, 2022.05. 02.490306, 2022 | 4 | 2022 |
| eP264: Genotype-phenotype correlation analysis and therapeutic development using a patient stem cell-derived disease model of Wolfram syndrome F Urano, RA Kitamura, K Maxwell, W Ye, K Kries, C Brown, ... Genetics in Medicine 24 (3), S167, 2022 | 1 | 2022 |
| Long-Term Survival of Participants in the CENTAUR Trial of AMX0035 for ALS (4550) S Paganoni, S Hendrix, S Dickson, N Knowlton, E Macklin, J Cohen, ... Neurology 96 (15_supplement), 4550, 2021 | 1 | 2021 |
| Long-term treatment with AMX0035 in the open-label extension of CENTAUR, a randomized controlled trial in individuals with amyotrophic lateral sclerosis S Paganoni, S Hendrix, S Dickson, N Ellison, K Hendrix, N Knowlton, ... MUSCLE & NERVE 62, S105-S105, 2020 | 1 | 2020 |
| P3‐037: CLINICAL TRIAL DESIGN FOR A PHASE II, RANDOMIZED, PLACEBO‐CONTROLLED TRIAL OF AMX0035 IN ALZHEIMER'S DISEASE KL Leslie, J Cohen, J Klee, V Williams, SE Arnold Alzheimer's & Dementia 14 (7S_Part_20), P1078-P1079, 2018 | 1 | 2018 |
| Biological effects of sodium phenylbutyrate and taurursodiol in Alzheimer's disease SE Arnold, S Hendrix, J Nicodemus‐Johnson, N Knowlton, VJ Williams, ... Alzheimer's & Dementia: Translational Research & Clinical Interventions 10 …, 2024 | | 2024 |
| Genotype-phenotype correlation analysis and therapeutic development using a patient stem cell-derived disease model of Wolfram syndrome RA Kitamura, KG Maxwell, W Ye, K Kries, CM Brown, P Augsornworawat, ... bioRxiv, 2021.11. 07.467657, 2021 | | 2021 |
| P. 059 Results From the Randomized and Open-Label Periods of the CENTAUR Trial of Sodium Phenylbutyrate and Ursodoxicoltaurine in Amyotrophic Lateral Sclerosis (ALS) S Paganoni, S Hendrix, SP Dickson, N Knowlton, J Cohen, J Klee, ... Canadian Journal of Neurological Sciences 48 (s3), S35-S35, 2021 | | 2021 |
| Functional and Long-Term Survival Data of AMX0035 in Amyotrophic Lateral Sclerosis: Results of the CENTAUR Trial S Paganoni, SM Healey, S Hendrix, SP Dickson, N Knowlton, J Cohen, ... NEUROTHERAPEUTICS 18 (3), 2139-2140, 2021 | | 2021 |
| ACCURATE TESTING OF LIMB ISOMETRIC STRENGTH (ATLIS (TM)) FOR MEASURING MUSCLE STRENGTH IN AMYOTROPHIC LATERAL SCLEROSIS: RESULTS FROM THE CENTAUR TRIAL S Paganoni, PL Andres, S Hendrix, S Dickson, N Ellison, K Hendrix, ... MUSCLE & NERVE 62, S104-S104, 2020 | | 2020 |
| Safety and Efficacy of a Fixed-Dose Coformulation of Sodium Phenylbutyrate and Taurursodiol in Alzheimer’s Disease: Results From the Phase 2 PEGASUS Study SE Arnold, SB Hendrix, J Nicodemus-Johnson, AJ McManus, KL Bell, ... 2021 Alzheimer's Association International Conference, 0 | | |
| Clinical trial design for a Phase II, randomized, placebo-controlled trial of AMX0035 in Alzheimer’s Disease (PEGASUS) KL Leslie, JB Klee, J Cohen, S Hendrix, VJ Williams, SE Arnold | | |
